Sangamo Therapeutics, Inc.(SGMO)Earnings, Financials & Key Ratios
SGMO•NASDAQ
$0.18
$38M mkt cap·Price updated May 6, 2026
AboutSangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.Show more
- Revenue$58M-67.2%
- EBITDA-$95M+62.4%
- Net Income-$98M+62.0%
- EPS (Diluted)-0.49+66.9%
- Gross Margin100%
- EBITDA Margin-163.68%-14.6%
- Operating Margin-179.88%-15.7%
- Net Margin-169.45%-15.8%
- ROE-185.39%-35.8%
- ROIC-178.84%-36.4%
- Debt/Equity1.34+192.0%
SGMO Key Insights
Sangamo Therapeutics, Inc. (SGMO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Sales declining 10.8% over 5 years
- ✗Shares diluted 15.6% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SGMO Price & Volume
Sangamo Therapeutics, Inc. (SGMO) stock price & volume — 10-year historical chart
Loading chart...
SGMO Growth Metrics
Sangamo Therapeutics, Inc. (SGMO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.34%
5 Years-10.81%
3 Years-19.48%
TTM-37.13%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM19.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM41.33%
Return on Capital
10 Years-43.42%
5 Years-60.05%
3 Years-84.95%
Last Year-119.91%
SGMO Recent Earnings
Sangamo Therapeutics, Inc. (SGMO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 3/12 qtrs (25%)
Q4 2025Latest
Nov 6, 2025EPS
$0.11
Est $0.03
-266.7%
Revenue
$581,000
Est $40M
-98.6%
Q3 2025
Aug 7, 2025EPS
$0.08
Est $0.07
-14.3%
Revenue
$18M
Est $34M
-46.8%
Q2 2025
May 12, 2025EPS
$0.14
Est $0.11
-27.3%
Revenue
$6M
Est $7M
-13.2%
Q2 2025
Mar 17, 2025EPS
$0.11
Est $0.09
-22.2%
Revenue
$8M
Est $12M
-35.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 6, 2025 | $0.11vs $0.03-266.7% | $581,000vs $40M-98.6% |
| Q3 2025 | Aug 7, 2025 | $0.08vs $0.07-14.3% | $18Mvs $34M-46.8% |
| Q2 2025 | May 12, 2025 | $0.14vs $0.11-27.3% | $6Mvs $7M-13.2% |
| Q2 2025 | Mar 17, 2025 | $0.11vs $0.09-22.2% | $8Mvs $12M-35.5% |
Based on last 12 quarters of dataView full earnings history →
SGMO Peer Comparison
Sangamo Therapeutics, Inc. (SGMO) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EDIT | 297.52M | 3.04 | -1.69 | -100% | -5.23% | 0.66 | ||
 CRSP | 4.92B | 52.38 | -8.10 | -89.97% | -13.29% | -25.49% | 0.11 | |
 BEAM | 2.97B | 28.90 | -35.68 | 120.01% | -57.24% | -7.31% | 0.24 | |
 NTLA | 1.55B | 13.31 | -3.49 | -100% | -61.47% | 0.14 | ||
 PRME | 612.07M | 3.39 | -2.51 | 55.28% | -43.42% | -178.61% | 0.96 | |
 FATE | 272.25M | 2.36 | -2.05 | -51.24% | -20.51% | -65.79% | 0.38 | |
 RCKT | 383.45M | 3.54 | -1.76 | -80.49% | 0.09 | |||
 ILMN | 21.13B | 139.07 | 25.52 | -0.78% | 19.43% | 32.84% | 4.41% | 0.94 |
Compare SGMO vs Peers
Sangamo Therapeutics, Inc. (SGMO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SGMO Income Statement
Sangamo Therapeutics, Inc. (SGMO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 19.39M | 36.57M | 84.45M | 102.43M | 118.19M | 110.7M | 111.3M | 176.23M | 57.8M | 32.88M |
| Revenue Growth % | -50.96% | 88.6% | 130.95% | 21.29% | 15.39% | -6.34% | 0.54% | 58.34% | -67.2% | -37.13% |
| Cost of Goods Sold | 65.62M | 65.73M | 114.87M | 145.92M | 180.65M | 0 | 12.11M | 0 | 0 | 0 |
| COGS % of Revenue | 338.43% | 179.75% | 136.01% | 142.46% | 152.84% | - | 10.88% | - | - | - |
| Gross Profit | -46.23M▲ 0% | -29.16M▲ 36.9% | -30.41M▼ 4.3% | -43.49M▼ 43.0% | -62.45M▼ 43.6% | 110.7M▲ 277.2% | 99.19M▼ 10.4% | 176.23M▲ 77.7% | 57.8M▼ 67.2% | 32.88M▲ 0% |
| Gross Margin % | -238.43% | -79.75% | -36.01% | -42.46% | -52.84% | 100% | 89.12% | 100% | 100% | 100% |
| Gross Profit Growth % | -67.56% | 36.92% | -4.3% | -43.01% | -43.59% | 277.25% | -10.4% | 77.67% | -67.2% | - |
| Operating Expenses | 91.95M | 92.93M | 161.6M | 61.69M | 67.1M | 294.04M | 300.47M | 450.24M | 161.77M | 141.9M |
| OpEx % of Revenue | 474.23% | 254.13% | 191.35% | 60.22% | 56.77% | 265.61% | 269.97% | 255.48% | 279.88% | - |
| Selling, General & Admin | 26.33M | 27.2M | 46.74M | 61.69M | 67.1M | 63.22M | 62.68M | 61.17M | 44.73M | 36.99M |
| SG&A % of Revenue | 135.8% | 74.38% | 55.34% | 60.22% | 56.77% | 57.11% | 56.32% | 34.71% | 77.38% | - |
| Research & Development | 65.62M | 65.73M | 114.87M | 145.92M | 180.65M | 230.82M | 249.9M | 234.06M | 111.52M | 104.91M |
| R&D % of Revenue | 338.43% | 179.75% | 136.01% | 142.46% | 152.84% | 208.51% | 224.53% | 132.81% | 192.94% | - |
| Other Operating Expenses | 887K | 0 | 0 | -145.92M | -180.65M | 0 | -12.11M | 155.01M | 5.52M | 0 |
| Operating Income | -72.56M▲ 0% | -56.36M▲ 22.3% | -77.15M▼ 36.9% | -105.18M▼ 36.3% | -129.55M▼ 23.2% | -183.34M▼ 41.5% | -201.28M▼ 9.8% | -274M▼ 36.1% | -103.97M▲ 62.1% | -109.03M▲ 0% |
| Operating Margin % | -374.23% | -154.13% | -91.35% | -102.69% | -109.61% | -165.61% | -180.85% | -155.48% | -179.88% | -331.64% |
| Operating Income Growth % | -54.86% | 22.32% | -36.89% | -36.33% | -23.17% | -41.52% | -9.79% | -36.13% | 62.06% | - |
| EBITDA | -71.56M | -54.86M | -74.79M | -101.25M | -123.87M | -165.7M | -189.17M | -251.81M | -94.61M | -101.17M |
| EBITDA Margin % | -369.09% | -150.03% | -88.56% | -98.85% | -104.8% | -149.68% | -169.97% | -142.89% | -163.68% | -307.75% |
| EBITDA Growth % | -56.02% | 23.34% | -36.32% | -35.38% | -22.34% | -33.77% | -14.17% | -33.11% | 62.43% | 22.06% |
| D&A (Non-Cash Add-back) | 997K | 1.5M | 2.36M | 3.93M | 5.68M | 17.64M | 12.11M | 22.19M | 9.36M | 7.85M |
| EBIT | -71.67M | -56.36M | -77.15M | -105.18M | -129.55M | -183.34M | -201.28M | -118.99M | -98.45M | -110.67M |
| Net Interest Income | 887K | 1.79M | 8.26M | 9.76M | 8.78M | 5.35M | 9.43M | 11.1M | 5.86M | 3.22M |
| Interest Income | 887K | 1.79M | 8.26M | 9.76M | 8.78M | 5.35M | 9.43M | 11.1M | 5.86M | 3.22M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 887K | 1.79M | 8.26M | 9.76M | 8.77M | 5.35M | 9.43M | 11.1M | 5.86M | -325K |
| Pretax Income | -71.67M▲ 0% | -54.57M▲ 23.9% | -68.89M▼ 26.2% | -95.42M▼ 38.5% | -120.78M▼ 26.6% | -177.99M▼ 47.4% | -191.85M▼ 7.8% | -262.9M▼ 37.0% | -98.11M▲ 62.7% | -109.35M▲ 0% |
| Pretax Margin % | -369.65% | -149.23% | -81.57% | -93.16% | -102.19% | -160.79% | -172.37% | -149.18% | -169.74% | -332.63% |
| Income Tax | -14K | 0 | 0 | 0 | 345K | 306K | 429K | -5.07M | -167K | -442K |
| Effective Tax Rate % | 0.02% | 0% | 0% | 0% | -0.29% | -0.17% | -0.22% | 1.93% | 0.17% | 0.4% |
| Net Income | -71.66M▲ 0% | -54.57M▲ 23.8% | -68.33M▼ 25.2% | -95.19M▼ 39.3% | -121M▼ 27.1% | -178.29M▼ 47.3% | -192.28M▼ 7.8% | -257.83M▼ 34.1% | -97.94M▲ 62.0% | -108.91M▲ 0% |
| Net Margin % | -369.58% | -149.23% | -80.91% | -92.93% | -102.37% | -161.05% | -172.76% | -146.3% | -169.45% | -331.28% |
| Net Income Growth % | -76.05% | 23.85% | -25.23% | -39.3% | -27.12% | -47.35% | -7.85% | -34.09% | 62.01% | 19.23% |
| Net Income (Continuing) | -71.66M | -54.57M | -68.89M | -95.42M | -121.12M | -178.3M | -192.28M | -257.83M | -97.94M | -108.91M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 739K | 185K | -868K | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.02▲ 0% | -0.70▲ 31.4% | -0.70▲ 0.0% | -0.68▲ 2.9% | -0.90▼ 32.4% | -1.23▼ 36.7% | -1.25▼ 1.6% | -1.48▼ 18.4% | -0.49▲ 66.9% | -0.36▲ 0% |
| EPS Growth % | -75.86% | 31.37% | 0% | 2.86% | -32.35% | -36.67% | -1.63% | -18.4% | 66.89% | 41.33% |
| EPS (Basic) | -1.02 | -0.70 | -0.70 | -0.68 | -0.90 | -1.23 | -1.25 | -1.48 | -0.49 | - |
| Diluted Shares Outstanding | 70.55M | 78.08M | 96.94M | 112.11M | 134.45M | 144.57M | 154.34M | 174.44M | 201.7M | 304.27M |
| Basic Shares Outstanding | 70.55M | 78.08M | 96.94M | 112.11M | 134.45M | 144.57M | 154.34M | 174.44M | 201.7M | 304.27M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SGMO Balance Sheet
Sangamo Therapeutics, Inc. (SGMO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 149.58M | 248.4M | 410.52M | 405.47M | 659.67M | 398.77M | 300.33M | 94.33M | 51.69M | 44.08M |
| Cash & Short-Term Investments | 142.76M | 244.56M | 400.51M | 362.47M | 641.42M | 376.55M | 277.63M | 81M | 41.92M | 30.53M |
| Cash Only | 22.06M | 49.83M | 140.42M | 80.43M | 131.33M | 178.87M | 100.44M | 45.2M | 41.92M | 30.53M |
| Short-Term Investments | 120.47M | 193.48M | 259.71M | 282.05M | 510.09M | 197.68M | 177.19M | 35.8M | 0 | 0 |
| Accounts Receivable | 5.2M | 3.58M | 5.05M | 37.59M | 6.26M | 6.36M | 4.47M | 4.07M | 4.6M | 5.13M |
| Days Sales Outstanding | 97.82 | 35.76 | 21.82 | 133.95 | 19.33 | 20.98 | 14.67 | 8.42 | 29.04 | 53.59 |
| Inventory | -224K | -1.25M | -375K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 1.51M | 5.34M | 0 | 0 | 0 | 0 | 9.26M | 5.17M | 8.42M |
| Total Non-Current Assets | 8.31M | 38.34M | 179.87M | 232.04M | 278.88M | 323.15M | 262.18M | 70.99M | 49.94M | 44.57M |
| Property, Plant & Equipment | 6.56M | 31.07M | 78.72M | 107.22M | 112.37M | 124.7M | 125.53M | 52.87M | 34.76M | 29.22M |
| Fixed Asset Turnover | 2.96x | 1.18x | 1.07x | 0.96x | 1.05x | 0.89x | 0.89x | 3.33x | 1.66x | 1.03x |
| Goodwill | 1.58M | 1.58M | 40.04M | 39.27M | 42.8M | 39.7M | 37.55M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 54.87M | 53.16M | 58.13M | 53.76M | 50.73M | 0 | 0 | 0 |
| Long-Term Investments | 0 | 1.01M | -6.71M | 21.83M | 50.53M | 88.17M | 29.84M | 1.5M | 1.5M | 4.5M |
| Other Non-Current Assets | 169K | 4.68M | 6.24M | 10.57M | 15.06M | 16.82M | 12.25M | 16.63M | 13.69M | 58.63M |
| Total Assets | 157.89M▲ 0% | 286.74M▲ 81.6% | 590.39M▲ 105.9% | 637.52M▲ 8.0% | 938.55M▲ 47.2% | 721.92M▼ 23.1% | 562.51M▼ 22.1% | 165.32M▼ 70.6% | 101.64M▼ 38.5% | 88.64M▲ 0% |
| Asset Turnover | 0.12x | 0.13x | 0.14x | 0.16x | 0.13x | 0.15x | 0.20x | 1.07x | 0.57x | 0.35x |
| Asset Growth % | -27.32% | 81.61% | 105.9% | 7.98% | 47.22% | -23.08% | -22.08% | -70.61% | -38.52% | -87.15% |
| Total Current Liabilities | 13.29M | 44.86M | 78.51M | 69.87M | 143.55M | 127.89M | 111.71M | 47.73M | 45.8M | 50.13M |
| Accounts Payable | 2.58M | 16K | 3.35M | 6.67M | 12.55M | 9.76M | 22.42M | 15.26M | 15.48M | 15.56M |
| Days Payables Outstanding | 14.35 | 0.09 | 10.66 | 16.69 | 25.36 | - | 675.8 | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 4.14M | 28.34M | 47.56M | 38.71M | 96.64M | 85.71M | 51.78M | 0 | 7.56M | 30.22M |
| Other Current Liabilities | 3.38M | 5.9M | 9.69M | 13.61M | 20.74M | 20.84M | 11.88M | 11.73M | 14.57M | 9.87M |
| Current Ratio | 11.25x | 5.54x | 5.23x | 5.80x | 4.60x | 3.12x | 2.69x | 1.98x | 1.13x | 1.13x |
| Quick Ratio | 11.27x | 5.57x | 5.23x | 5.80x | 4.60x | 3.12x | 2.69x | 1.98x | 1.13x | 1.13x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 53.59 |
| Total Non-Current Liabilities | 8.4M | 53.98M | 144.63M | 134.91M | 297.64M | 218.69M | 155.84M | 34.7M | 33.06M | 32.27M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 3.94M | 24.74M | 27.69M | 41.19M | 38.4M | 44.05M | 38.99M | 33.52M | 26.25M | 100.01M |
| Deferred Tax Liabilities | -3.94M | -24.74M | 6.71M | 6.57M | 7.18M | 6.64M | 6.27M | 0 | 0 | 15K |
| Other Non-Current Liabilities | 0 | 0 | 1.96M | 5.71M | 7.01M | 1.22M | 1.21M | 1.19M | 933K | 3.81M |
| Total Liabilities | 21.7M | 98.84M | 223.88M | 204.78M | 441.18M | 346.58M | 267.55M | 82.43M | 78.86M | 82.4M |
| Total Debt | 3.94M | 24.74M | 27.69M | 44.41M | 42.09M | 48.08M | 43.11M | 38.1M | 30.57M | 25.42M |
| Net Debt | -18.12M | -25.09M | -112.73M | -36.02M | -89.24M | -130.79M | -57.34M | -7.1M | -11.35M | -5.1M |
| Debt / Equity | 0.03x | 0.13x | 0.08x | 0.10x | 0.08x | 0.13x | 0.15x | 0.46x | 1.34x | 1.34x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.25x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.05x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 136.19M▲ 0% | 187.9M▲ 38.0% | 367.26M▲ 95.5% | 432.74M▲ 17.8% | 497.37M▲ 14.9% | 375.34M▼ 24.5% | 294.96M▼ 21.4% | 82.89M▼ 71.9% | 22.77M▼ 72.5% | 6.24M▲ 0% |
| Equity Growth % | -29.23% | 37.96% | 95.45% | 17.83% | 14.93% | -24.53% | -21.42% | -71.9% | -72.53% | -265.18% |
| Book Value per Share | 1.93 | 2.41 | 3.79 | 3.86 | 3.70 | 2.60 | 1.91 | 0.48 | 0.11 | 0.02 |
| Total Shareholders' Equity | 136.19M | 187.9M | 366.52M | 432.55M | 498.23M | 375.34M | 294.96M | 82.89M | 22.77M | 6.24M |
| Common Stock | 709K | 856K | 1.02M | 1.16M | 1.42M | 1.46M | 1.67M | 1.78M | 2.13M | 3.22M |
| Retained Earnings | -440.91M | -495.48M | -562.7M | -656.99M | -777.98M | -956.27M | -1.15B | -1.41B | -1.5B | -1.59B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 20K | -286K | -1.44M | -2.45M | 5.42M | -3.99M | -8.4M | -4.59M | -7.53M | -1.45M |
| Minority Interest | 0 | 0 | 739K | 185K | -868K | 0 | 0 | 0 | 0 | 0 |
SGMO Cash Flow Statement
Sangamo Therapeutics, Inc. (SGMO) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -65.88M | 11.18M | 37.15M | -144.4M | 169.88M | -233.25M | -223.63M | -224.84M | -67.14M | -67.14M |
| Operating CF Margin % | -339.8% | 30.57% | 43.99% | -140.98% | 143.73% | -210.7% | -200.92% | -127.58% | -116.16% | - |
| Operating CF Growth % | -95.38% | 116.97% | 232.34% | -488.68% | 217.64% | -237.31% | 4.13% | -0.54% | 70.14% | -170.26% |
| Net Income | -71.66M | -54.57M | -68.89M | -95.42M | -121.12M | -178.3M | -192.28M | -257.83M | -97.94M | -108.91M |
| Depreciation & Amortization | 997K | 1.5M | 2.36M | 9.61M | 13.37M | 17.64M | 20.56M | 22.19M | 9.36M | 7.85M |
| Stock-Based Compensation | 15.06M | 9.09M | 14.68M | 19.33M | 25.71M | 32.96M | 31.65M | 27.36M | 12.38M | 10.23M |
| Deferred Taxes | -14K | -661K | -5.23M | -5.13M | 0 | 2.77M | 0 | -6.33M | 0 | -18K |
| Other Non-Cash Items | 320K | 80K | 966K | 218K | -666K | -6.43M | -1.24M | 153.8M | 4.55M | -657K |
| Working Capital Changes | -10.59M | 55.74M | 93.27M | -73.01M | 252.59M | -101.89M | -82.32M | -164.03M | 4.51M | 15.34M |
| Change in Receivables | -2.14M | 1.63M | -1.33M | -32.24M | 31.68M | -789K | 2.33M | -976K | 953K | 10.13M |
| Change in Inventory | -1.03M | -685K | -1M | 4.19M | -10.7M | 7.66M | 0 | 0 | 0 | 0 |
| Change in Payables | -2.33M | 3.22M | -6.37M | -4.19M | 10.7M | -7.66M | 13.35M | 5.59M | -14.17M | -3.02M |
| Cash from Investing | 18.13M | -80.9M | -178.11M | -59.8M | -271.63M | 248.2M | 59.28M | 153.53M | 37.52M | 1.24M |
| Capital Expenditures | -732K | -3.75M | -43.06M | -20.68M | -14.71M | -23.28M | -20.17M | -21.16M | -267K | -240K |
| CapEx % of Revenue | 3.78% | 10.26% | 50.99% | 20.18% | 12.45% | 21.03% | 18.12% | 12% | 0.46% | - |
| Acquisitions | 0 | 0 | -75.65M | -262K | -704K | -119K | -79.46M | 0 | 1.95M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 18.86M | -3.5M | -59.39M | 0 | 0 | 0 | 79.46M | 0 | 0 | 1.48M |
| Cash from Financing | 337K | 97.49M | 231.71M | 142.03M | 153.1M | 32.86M | 84.66M | 14.59M | 28.38M | 62.94M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1.11M | 81.57M | 215.76M | 136.31M | 142.53M | 27.1M | 84.87M | 15.11M | 28.99M | 65.93M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -776K | 15.92M | 15.95M | 5.72M | 10.57M | 5.76M | -209K | -518K | -614K | -2.99M |
| Net Change in Cash | -47.42M▲ 0% | 27.77M▲ 158.6% | 90.59M▲ 226.3% | -61.99M▼ 168.4% | 50.9M▲ 182.1% | 47.54M▼ 6.6% | -78.43M▼ 265.0% | -55.24M▲ 29.6% | -3.29M▲ 94.1% | -8.67M▲ 0% |
| Free Cash Flow | -66.61M▲ 0% | 7.43M▲ 111.2% | -5.91M▼ 179.6% | -165.08M▼ 2691.8% | 155.16M▲ 194.0% | -256.53M▼ 265.3% | -243.8M▲ 5.0% | -246M▼ 0.9% | -67.41M▲ 72.6% | -76.4M▲ 0% |
| FCF Margin % | -343.57% | 20.31% | -7% | -161.16% | 131.28% | -231.73% | -219.05% | -139.59% | -116.62% | -232.38% |
| FCF Growth % | -84.37% | 111.15% | -179.6% | -2691.76% | 193.99% | -265.33% | 4.96% | -0.9% | 72.6% | 34.77% |
| FCF per Share | -0.94 | 0.10 | -0.06 | -1.47 | 1.15 | -1.77 | -1.58 | -1.41 | -0.33 | -0.33 |
| FCF Conversion (FCF/Net Income) | 0.92x | -0.20x | -0.54x | 1.52x | -1.40x | 1.31x | 1.16x | 0.87x | 0.69x | 0.70x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SGMO Key Ratios
Sangamo Therapeutics, Inc. (SGMO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -43.61% | -33.67% | -24.62% | -23.8% | -26.02% | -40.86% | -57.37% | -136.47% | -185.39% | -813.95% |
| Return on Invested Capital (ROIC) | -45.15% | -30.1% | -27.73% | -24.23% | -24.14% | -42.14% | -62.62% | -131.14% | -178.84% | -178.84% |
| Gross Margin | -238.43% | -79.75% | -36.01% | -42.46% | -52.84% | 100% | 89.12% | 100% | 100% | 100% |
| Net Margin | -369.58% | -149.23% | -80.91% | -92.93% | -102.37% | -161.05% | -172.76% | -146.3% | -169.45% | -331.28% |
| Debt / Equity | 0.03x | 0.13x | 0.08x | 0.10x | 0.08x | 0.13x | 0.15x | 0.46x | 1.34x | 1.34x |
| FCF Conversion | 0.92x | -0.20x | -0.54x | 1.52x | -1.40x | 1.31x | 1.16x | 0.87x | 0.69x | 0.70x |
| Revenue Growth | -50.96% | 88.6% | 130.95% | 21.29% | 15.39% | -6.34% | 0.54% | 58.34% | -67.2% | -37.13% |
SGMO Frequently Asked Questions
Sangamo Therapeutics, Inc. (SGMO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Sangamo Therapeutics, Inc. (SGMO) reported $32.9M in revenue for fiscal year 2024. This represents a 1394% increase from $2.2M in 1999.
Sangamo Therapeutics, Inc. (SGMO) saw revenue decline by 67.2% over the past year.
Sangamo Therapeutics, Inc. (SGMO) reported a net loss of $108.9M for fiscal year 2024.
Dividend & Returns
Sangamo Therapeutics, Inc. (SGMO) has a return on equity (ROE) of -185.4%. Negative ROE indicates the company is unprofitable.
Sangamo Therapeutics, Inc. (SGMO) had negative free cash flow of $76.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More SGMO
Sangamo Therapeutics, Inc. (SGMO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates